Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 3/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599782 | 0.83 | TRPV1 (0.49) | XIAPTRPV1DRD2HTR2ADRD3 | |
| SCHEMBL14277888 | 0.83 | TRPV1 (0.49) | XIAPTRPV1DRD2HTR2ADRD3 | |
| SCHEMBL803487 | 0.83 | TRPV1 (0.49) | XIAPTRPV1DRD2HTR2ADRD3 | |
| SCHEMBL14452760 | 0.83 | TRPV1 (0.49) | XIAPTRPV1DRD2HTR2ADRD3 | |
| SCHEMBL4226632 | 0.83 | TRPV1 (0.54) | XIAPTRPV1BRD4CREBBPCNR1 | |
| SCHEMBL4226634 | 0.83 | TRPV1 (0.54) | XIAPTRPV1BRD4CREBBPCNR1 | |
| SCHEMBL26962614 | 0.81 | TRPV1 (0.50) | XIAPTRPV1BRD4CREBBPCNR1 | |
| SCHEMBL27125516 | 0.81 | TRPV1 (0.50) | XIAPTRPV1BRD4CREBBPCNR1 | |
| SCHEMBL25472337 | 0.81 | XIAP (0.52) | XIAPTRPV1BIRC3BIRC2 | |
| SCHEMBL20622055 | 0.80 | TRPV1 (0.49) | XIAPTRPV1P2RX7BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | XIAP 1331/4885TRPV1 3405/4885P2RX7 1425/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | XIAP 1331/4885TRPV1 3405/4885P2RX7 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.